Search

CN-121987743-A - Traditional Chinese medicine compound composition for treating rheumatoid arthritis and preparation method and application thereof

CN121987743ACN 121987743 ACN121987743 ACN 121987743ACN-121987743-A

Abstract

The invention discloses a traditional Chinese medicine compound composition for treating rheumatoid arthritis and a preparation method and application thereof, wherein the traditional Chinese medicine compound composition is prepared from 15-45 parts of salvia miltiorrhiza, 6-18 parts of ligusticum wallichii, 9-27 parts of turmeric, 10-30 parts of caulis spatholobi, 10-30 parts of gentiana macrophylla, 10-30 parts of mulberry twig, 10-30 parts of polygonum cuspidatum, 10-30 parts of radix cyathulae, 6-18 parts of earthworm and 10-30 parts of fried white paeony root. The traditional Chinese medicine compound composition provided by the invention is based on the theory of traditional Chinese medicine under the guidance of the pathogenesis of Rheumatoid Arthritis (RA), and based on the core idea of 'dredging collaterals and releasing arthralgia', is treated by differentiation of symptoms and treatment, and is obtained by screening a large number of experiments. The animal experiment and clinical research show that the Chinese herbal compound composition provided by the invention has good efficacy of treating rheumatoid arthritis and is worthy of popularization.

Inventors

  • Jing Rongyue
  • Tao Xincheng

Assignees

  • 南京市中医院
  • 江苏省人民医院（南京医科大学第一附属医院）

Dates

Publication Date
20260508
Application Date
20250520

Claims (8)

  1. 1. A traditional Chinese medicine compound composition for treating rheumatoid arthritis is characterized by comprising the following raw materials: Radix Salviae Miltiorrhizae, rhizoma Chuanxiong, rhizoma Curcumae Longae, caulis Spatholobi, radix Gentianae Macrophyllae, ramulus Mori, rhizoma Polygoni Cuspidati, radix Cyathulae, pheretima, and radix Paeoniae alba preparata.
  2. 2. The traditional Chinese medicine compound composition for treating rheumatoid arthritis according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 15-45 parts of radix salviae miltiorrhizae, 6-18 parts of ligusticum wallichii, 9-27 parts of turmeric, 10-30 parts of caulis spatholobi, 10-30 parts of radix gentianae macrophyllae, 10-30 parts of ramulus mori, 10-30 parts of polygonum cuspidatum, 10-30 parts of radix cyathulae, 6-18 parts of earthworm and 10-30 parts of fried radix paeoniae alba.
  3. 3. The traditional Chinese medicine compound composition for treating rheumatoid arthritis according to claim 2, which is characterized by being prepared from the following raw materials in parts by weight: 15-30 parts of red sage root, 6-12 parts of szechuan lovage rhizome 9-18 parts of turmeric 10-20 parts of suberect spatholobus stem, 10-20 parts of gentiana macrophylla, and 10-20 parts of mulberry twig, 10-20 parts of giant knotweed, 10-20 parts of medicinal cyathula root, 6-12 parts of earthworm and 10-20 parts of stir-fried white paeony root.
  4. 4. The traditional Chinese medicine compound composition for treating rheumatoid arthritis according to claim 3, which is characterized by being prepared from the following raw materials in parts by weight: 15 parts of red sage root, 6 parts of szechuan lovage rhizome, 9 parts of turmeric, 10 parts of suberect spatholobus stem, 10 parts of large-leaved gentian, 10 parts of mulberry twig, 10 parts of giant knotweed, 10 parts of medicinal cyathula root, 6 parts of earthworm and 10 parts of stir-fried white paeony root.
  5. 5. The method for preparing the traditional Chinese medicine compound composition according to any one of claims 1 to 4, which is characterized by comprising the following steps: Firstly taking the root of red-rooted salvia, the rhizome of chuanxiong, turmeric, suberect spatholobus stem, large-leaved gentian, mulberry twig, giant knotweed, medicinal cyathula root, earthworm and stir-fried white paeony root according to the weight parts, soaking in water, decocting in water, filtering, mixing filtrates, and drying under reduced pressure to obtain extract.
  6. 6. The method for preparing the compound Chinese medicinal composition according to claim 5, comprising the following steps: Firstly, taking the root of red-rooted salvia, the rhizome of chuanxiong, the rhizome of turmeric, the spatholobus stem, the gentiana macrophylla, the mulberry twig, the giant knotweed, the medicinal cyathula root, the earthworm and the fried white peony root according to parts by weight, soaking in water for 1-2 hours, placing in a multifunctional extraction tank, adding 5-15 times of water, decocting and extracting for 1-3 times, filtering each time for 1-3 hours, combining the filtrates, and drying under reduced pressure to obtain the extract.
  7. 7. A traditional Chinese medicine preparation for treating rheumatoid arthritis, which is characterized in that the extract prepared in the claim 5 or 6 and a pharmaceutically acceptable carrier are prepared into granules, tablets, capsules, pills, oral liquid, powder, mixture or ointment.
  8. 8. The use of a compound Chinese medicinal composition according to any one of claims 1-4 in the preparation of a medicament for treating rheumatoid arthritis.

Description

Traditional Chinese medicine compound composition for treating rheumatoid arthritis and preparation method and application thereof Technical Field The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine compound composition for treating rheumatoid arthritis and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. Background In recent years, rheumatoid arthritis (Rheumatoid arthritis, RA) has remained one of the five major refractory diseases in the medical community. RA is a chronic and progressive autoimmune disease, is mainly characterized by joint swelling and pain caused by persistent synovial hyperplasia accompanied by massive immune cell infiltration, and can involve multiple organs and systems such as lungs, cardiovascular systems, nerves and the like. RA pathogenesis is complex, involves genetic, immune, environmental, and other multi-factor interactions, and it is difficult to find single therapeutic targets. Even with clinical remission, there may still be long-term survival of autoimmune T/B cells in the patient, leading to a risk of relapse. In clinical treatment, about 30-40% of patients do not respond to traditional Disease-modifying anti-rheumatic drugs (DMARDs) or biological agents, and part of patients develop secondary resistance later. The use of modern medical drugs such as hormones, DMARDs or biological agents has multiple risks of increasing infection and malignant tumor, causing pulmonary fibrosis, inducing osteoporosis, diabetes, cardiovascular diseases and the like. Thus, new clinical drugs are urgently needed for the treatment of RA. The traditional Chinese medicine has long been known and treated for RA, but has no name of the disease, but can be classified into the category of arthralgia syndrome according to clinical manifestations, and is also called as "obstinate arthralgia" and "rheumatoid arthritis" due to complex disease condition, lingering course, joint movement disorder or even distortion. According to traditional Chinese medicine, arthralgia syndrome is caused by blockage of qi and blood of channels and collaterals due to invasion of exogenous pathogenic factors such as wind, cold, dampness, heat and the like, and is manifested by limb joint pain, numbness and limited movement. In the case of Lin Zhi Yu Yi Bian Fang (medical records of the clinical guidelines), the primary disease is in the meridian, and the chronic disease enters the collaterals. In the early stage of arthralgia syndrome, pathogenic qi invades meridians, and if the disease persists, the disease enters collaterals, exogenous pathogenic factors and phlegm stasis mutually combine to damage collaterals, and collaterals are formed. The stagnation of collaterals may cause local qi and blood malnutrition, and pathogenic wind and other external pathogenic factors are more likely to run into the body, induce or aggravate arthralgia syndrome, and appear as fixed stinging and joint deformation. Therefore, the "Nei Jing" mentions "treating wind first treating blood and blood going wind self-extinguishing". Meanwhile, modern researches suggest that the pathological changes of the arthralgia syndrome, such as microcirculation disturbance, fibrosis and the like are consistent with the theory of 'collateral diseases' in traditional Chinese medicine, and the vein relaxing method can play a role in improving microcirculation, inhibiting inflammation and other mechanisms. The inventor of the patent provides the theory of 'treating arthralgia from collaterals' innovatively on the basis of more than ten years of clinical and experimental researches, and emphasizes the important role of 'dredging collaterals and releasing arthralgia' in RA treatment. RA is a chronic and progressive autoimmune disease, which is a "arthralgia syndrome" in traditional Chinese medicine, and also accords with the manifestation of "collateral diseases", although the temporary symptoms are cold, heat, deficiency and excess, the collateral obstruction is always the common pathological feature, so the "dredging collaterals and releasing arthralgia" has important significance in treating the disease. Disclosure of Invention According to the clinical experience of traditional Chinese medicine, the invention stands on the core idea of 'dredging collaterals and releasing arthralgia', and the composition and the dosage of the medicinal flavor of the traditional Chinese medicine compound composition are screened and determined, so that the traditional Chinese medicine compound composition has good treatment effect through clinical and animal experiments. The invention also aims to provide a preparation method and application of the traditional Chinese medicine compound composition. The technical scheme adopted by the invention is as follows: A Chinese medicinal compound composition for treating rheumatoid arthritis comprises the following raw materia